Pirtobrutinib in Hard-to-Treat CLL/SLL: Promising Early Data.

Published Date: 15 Jul 2023

The BTK inhibitor produced an overall response in the majority of patients with CLL or SLL who had received extensive prior treatment in an early-phase trial, but infections, bleeding, and neutropenia were frequent side effects.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

2.

The main subject is associated with suicide in the United States.

3.

Alkem introduces cetuximab under the trade name Cetuxa in India.

4.

Firefighters who eat better can combat cancer.

5.

How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot